mp.weixin.qq.com·· 4 hours agoPickScore81
Veradermics Oral Extended-Release Minoxidil VDPHL01 Meets Primary Endpoint in Phase 3 Trial
In brief
Veradermics announced that its oral extended-release minoxidil, VDPHL01, met the primary and secondary endpoints in the Phase 3 Study 304. The randomized, double-blind, placebo-controlled study enrolled 536 men with mild to moderate androgenetic alopecia. After six months of treatment, mean non-vellus hair counts per square centimeter of scalp increased by 28.6 in the once-daily group and 36.4 in the twice-daily group, versus 6.6 with placebo; separation from placebo reached statistical significance by month 2.
Why it matters
Provides Phase 3 efficacy and safety data for oral extended-release minoxidil that can be compared directly with existing topical options.
Source: mp.weixin.qq.com · mp.weixin.qq.com